For its third fiscal quarter (ending September 30), Sage Therapeutics Inc (NASDAQ: SAGE) has reported E.P.S. of $-3.37 compared to $-2.31 a year ago. Relative to the consensus estimate of $-2.69, this was a shortfall of $-0.68. For the latest four quarters through September 30, E.P.S. were $-10.98 versus $-8.63 for the same period a year ago.
Recent Price Action
On 11/7/23, Sage Therapeutics Inc (NASDAQ: SAGE) stock suffered a large decline of -4.8%, closing at $19.63. Relative to the market the stock has been extremely weak over the last nine months but has risen 5.5% during the last week.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to be in line with the cost of capital, SAGE is expected to continue to be Value Creation neutral.
Sage Therapeutics has a current Value Trend Rating of F (Lowest Rating). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing complementary signals. Sage Therapeutics has a slightly negative Appreciation Score of 33 and a very low Power Rating of 15, triggering the Lowest Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment